Hormonal
Dapagliflozin monotherapy reduces hepatocyte injury biomarkers and FGF21 levels, suggesting a disease-modifying effect on NAFLD/NASH, but this effect is negated when combined with OM-3CA.
Dapagliflozin alone (10 mg daily) significantly reduces markers of liver cell injury (such as AST, ALT, and GGT) and FGF21 in patients with Type 2 Diabetes and NAFLD, suggesting it may modify the disease. However, adding OM-3CA (4 g daily) negates this specific benefit on injury biomarkers, even though the combination is superior for reducing total liver fat.
Dapagliflozin monotherapy reduced levels of all measured hepatocyte injury biomarkers... There was no significant effect of the OM-3CA monotherapy or the combination therapy on any of the hepatocyte injury biomarkers.
Why this rating
Double-blind, randomised, placebo-controlled trial.
Source
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Jan W. Eriksson et al. · Diabetologia · 2018
DOI 10.1007/s00125-018-4675-2
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →